KRP-104

De novo discovery of any therapeutic (e.g. antibodies, vaccines or small mols.) takes years to move from idea/preclinic to market release and is not a short-term solution for the current SARS-CoV-2 pandemic.Therefore, drug repurposing - the discovery of novel indication areas for already approved drugs is perhaps the only approach able to yield a short-term solutionIn order to repurpose drugs as potential inhibitors of SARS-CoV-2 proteases 3CLpro and PLpro, we performed a computational screening using the oral bioavailable antidiabetic drug class of gliptins as candidates.The orally bioavailable antidiabetic drug class of gliptins is safe and has been clin. available (and used by millions of patients) since 2006.Based on our repurposing hypothesis and our computational docking we predict the nitrile containing gliptins to inhibit the SARS-CoV-2 proteases 3CLpro and PLpro.As a result, nitrile containing gliptins deserve further investigation as potential anti-COVID19 drugs.